Showing results (1-10 of 32) with videos related to
Sort By:
Pageof 4
Journal of Pharmacokinetics and Pharmacodynamics|March 4, 2021
The power of modelling pulsatile profilesMichiel J van Esdonk, Jasper StevensEuropean Journal of Clinical Pharmacology|February 12, 2021
Predictive performance of parent-metabolite population pharmacokinetic models of (S)-ketamine in healthy volunteersM E Otto, K R Bergmann, G Jacobs, et al.Journal of Pharmacokinetics and Pharmacodynamics|May 13, 2017
A two-step deconvolution-analysis-informed population pharmacodynamic modeling approach for drugs targeting pulsatile endogenous compoundsMichiel J van Esdonk, Jacobus Burggraaf, Piet H van der Graaf, et al.British Journal of Clinical Pharmacology|February 23, 2020
Model informed quantification of the feed-forward stimulation of growth hormone by growth hormone-releasing hormoneMichiel J van Esdonk, Jacobus Burggraaf, Piet H van der Graaf, et al.Journal of Pharmacokinetics and Pharmacodynamics|April 6, 2020
Quantification of the endogenous growth hormone and prolactin lowering effects of a somatostatin-dopamine chimera using population PK/PD modelingMichiel J van Esdonk, Jacobus Burggraaf, Marion Dehez, et al.Clinical and Translational Science|July 14, 2021
Accelerating vaccine trial conduct in a pandemic with a hot spot-based inclusion strategy using trial and epidemic simulationJohan L van der Plas, Michiel J van Esdonk, Ingrid M C Kamerling, et al.CPT: Pharmacometrics & Systems Pharmacology|July 26, 2018
Population Pharmacokinetic/Pharmacodynamic Analysis of Nociceptive Pain Models Following an Oral Pregabalin Dose Administration to Healthy SubjectsMichiel J van Esdonk, Ian Lindeman, Pieter Okkerse, et al.CPT: Pharmacometrics & Systems Pharmacology|August 8, 2023
Item response theory in early phase clinical trials: Utilization of a reference model to analyze the Montgomery-Åsberg Depression Rating ScaleMarije E Otto, Kirsten R Bergmann, Marieke L de Kam, et al.British Journal of Clinical Pharmacology|July 27, 2022
Dose escalations in phase I studies: Feasibility of interpreting blinded pharmacodynamic dataGerardus J Hassing, Michiel J van Esdonk, Gerard J P van Westen, et al.Therapeutic Drug Monitoring|July 12, 2021
Theoretical Performance of Nonlinear Mixed-Effect Models Incorporating Saliva as an Alternative Sampling Matrix for Therapeutic Drug Monitoring in Pediatrics: A Simulation StudyMatthijs D Kruizinga, Frederik E Stuurman, Gertjan J A Driessen, et al.Pageof 4